title: Agonist pharmacology at recombinant α1A - and α1L -adrenoceptors and in lower urinary tract α1 -adrenoceptors.
abstract: OBJECTIVE
  Two distinct α1 -adrenoceptor phenotypes (α1A and α1L ) have recently been demonstrated to originate from a single α1A -adrenoceptor gene. Here, we examined the agonist profiles of recombinant α1A and α1L phenotypes and of lower urinary tract (LUT) α1 -adrenoceptors.
  
  
  METHODS
  A series of drugs (A61603, Ro 115-1240, NS-49 , MK017 and ESR1150) originally developed for stress urinary incontinence (SUI) therapy were used to stimulate recombinant α1A - and α1L -adrenoceptor phenotypes, and their potencies and intrinsic activity estimated from Ca(2+) responses. Agonist-induced contractions were also examined in LUT tissues of rats and humans and in human mesenteric artery and rat tail artery.
  
  
  RESULTS
  All the drugs were potent agonists of the α1A -adrenoceptor compared with the α1L -adrenoceptor phenotype. Among them, Ro 115-1240 was shown to be an α1A -specific partial agonist that produced partial contractions through α1A -adrenoceptors in rat prostate and tail artery, but not in the other LUT tissues and human mesenteric artery. In contrast, P-come 102 showed full agonist activity at α1A - and α1L -adrenoceptors, but was less selective than noradrenaline for α1A -adrenoceptors. Like noradrenaline, P-come 102 was highly potent at inducing contractions in all of the LUT tissues tested. However, the potency and intrinsic activity of P-come 102 were significantly lower than those of noradrenaline in human mesenteric artery.
  
  
  CONCLUSIONS
  The α1A - and α1L -adrenoceptor phenotypes and LUT α1 -adrenoceptors were demonstrated to have distinct agonist profiles. As adrenergic contractions in LUT are predominantly mediated through α1L -adrenoceptors, the development of α1L -selective agonists may provide clinically useful drugs for SUI therapy.
authors.affiliation: Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, School of Medicine, University of Fukui, Fukui, Japan.
authors.forename: Hatsumi
authors.initials: H
authors.lastname: Yoshiki
authors.forename: Junsuke
authors.initials: J
authors.lastname: Uwada
authors.forename: Hidenori
authors.initials: H
authors.lastname: Umada
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Takahashi
authors.forename: Tomio
authors.initials: T
authors.lastname: Yamakawa
authors.forename: Akio
authors.initials: A
authors.lastname: Yamaguchi
authors.forename: Osamu
authors.initials: O
authors.lastname: Yokoyama
authors.forename: Ikunobu
authors.initials: I
authors.lastname: Muramatsu
mesh_terms: D058646:Adrenergic alpha-1 Receptor Agonists / Q000494:pharmacology*; D000368:Aged; D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D016466:CHO Cells; D002118:Calcium / Q000502:physiology; D003412:Cricetulus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology*; D011994:Recombinant Proteins; D014521:Urethra / Q000187:drug effects / Q000502:physiology; D001743:Urinary Bladder / Q000187:drug effects* / Q000502:physiology
chemical_list: D058646:Adrenergic alpha-1 Receptor Agonists; D018340:Receptors, Adrenergic, alpha-1; D011994:Recombinant Proteins; D002118:Calcium
keywords: agonist profile; lower urinary tract; α1A-adrenoceptor; α1L-adrenoceptor
references.citation: J Urol. 1999 Nov;162(5):1829-32
references.pmid: 10524943
references.citation: Mol Pharmacol. 1994 Apr;45(4):703-8
references.pmid: 8183249
references.citation: Pharmacol Rev. 2010 Jun;62(2):265-304
references.pmid: 20392808
references.citation: Br J Pharmacol. 2010 Aug;160(7):1577-9
references.pmid: 20649561
references.citation: Pharmacol Rev. 1993 Sep;45(3):253-308
references.pmid: 8248281
references.citation: Br J Pharmacol. 2008 Sep;155(1):103-9
references.pmid: 18552869
references.citation: Br J Pharmacol. 2008 Apr;153(7):1485-94
references.pmid: 18223667
references.citation: Arch Int Pharmacodyn Ther. 1963;143:299-330
references.pmid: 13996119
references.citation: Br J Pharmacol. 2010 Aug;160(7):1573-6
references.pmid: 20649560
references.citation: J Pharmacol Exp Ther. 1997 Jun;281(3):1284-93
references.pmid: 9190864
references.citation: J Pharmacol Exp Ther. 2004 Sep;310(3):995-1002
references.pmid: 15100386
references.citation: World J Urol. 2002 Apr;19(6):390-6
references.pmid: 12022707
references.citation: Br J Pharmacol. 1990 Jan;99(1):197-201
references.pmid: 1970493
references.citation: Mol Pharmacol. 1991 Dec;40(6):876-83
references.pmid: 1661838
references.citation: Br J Pharmacol. 1999 May;127(1):19-26
references.pmid: 10369451
references.citation: Clin Sci (Lond). 1985;68 Suppl 10:15s-19s
references.pmid: 2857612
references.citation: Eur Urol. 1999;36 Suppl 1:17-22
references.pmid: 10393468
references.citation: Mol Pharmacol. 1996 Feb;49(2):209-15
references.pmid: 8632751
references.citation: Br J Pharmacol. 2006 Feb;147 Suppl 2:S88-119
references.pmid: 16465187
references.citation: Circ Res. 1996 May;78(5):737-49
references.pmid: 8620593
references.citation: Eur J Pharmacol. 1995 Nov 30;291(3):327-34
references.pmid: 8719417
references.citation: Nat Chem Biol. 2008 Jul;4(7):397-403
references.pmid: 18560432
references.citation: Br J Pharmacol. 2004 Feb;141(3):468-76
references.pmid: 14718262
references.citation: J Pharmacol Exp Ther. 1995 Jul;274(1):97-103
references.pmid: 7616455
references.citation: Br J Pharmacol. 1995 Jul;115(5):781-6
references.pmid: 8548177
references.citation: Br J Pharmacol. 2011 Nov;164 Suppl 1:S1-324
references.pmid: 22040146
references.citation: BJU Int. 2004 Jan;93(1):162-70
references.pmid: 14678390
references.citation: Br J Pharmacol. 2008 Nov;155(6):906-12
references.pmid: 18695643
references.citation: Br J Pharmacol. 1997 Mar;120(5):819-26
references.pmid: 9138687
references.citation: Mol Pharmacol. 2011 Feb;79(2):298-307
references.pmid: 20978120
references.citation: J Urol. 2000 Aug;164(2):578-83
references.pmid: 10893647
references.citation: J Urol. 2007 Jan;177(1):377-81
references.pmid: 17162094
references.citation: Biochim Biophys Acta. 1991 Oct 26;1095(2):127-39
references.pmid: 1657194
references.citation: Eur J Pharmacol. 1993 Nov 16;249(3):307-15
references.pmid: 7904564
references.citation: Pharmacol Rev. 1995 Jun;47(2):267-70
references.pmid: 7568329
references.citation: Life Sci. 1994;54(21):1595-605
references.pmid: 8196478
references.citation: Br J Pharmacol. 2012 Mar;165(5):1226-34
references.pmid: 21745191
references.citation: Br J Pharmacol. 2008 Dec;155(8):1224-34
references.pmid: 18806813
references.citation: Circulation. 1999 Dec 7;100(23):2336-43
references.pmid: 10587338
references.citation: BJU Int. 2004 Jan;93(1):78-83
references.pmid: 14678373
references.citation: Pharmacol Ther. 2000 Dec;88(3):281-309
references.pmid: 11337028
references.citation: J Pharmacol Sci. 2005 Feb;97(2):273-83
references.pmid: 15699575
references.citation: J Pharmacol Sci. 2010;113(2):169-81
references.pmid: 20508391
references.citation: Jpn J Pharmacol. 1993 Jul;62(3):297-304
references.pmid: 8105125
references.citation: Eur J Pharmacol. 2000 Dec 15;409(3):301-12
references.pmid: 11108825
references.citation: Eur J Pharmacol. 1997 May 26;327(1):25-32
references.pmid: 9185832
references.citation: J Urol. 1993 Aug;150(2 Pt 1):546-51
references.pmid: 7686987
references.citation: J Pharmacol Exp Ther. 2000 Nov;295(2):627-33
references.pmid: 11046098
references.citation: Pharmacol Rev. 2004 Dec;56(4):581-631
references.pmid: 15602011